ScholarIQanswers from OpenAlex
Texas Health Dallas
InstitutionResearch output, impact & collaborations
Texas Health Dallas is a institution indexed in ScholarIQ from OpenAlex.
What is known about Texas Health Dallas?
ScholarIQrecord summary
Texas Health Dallas is a research organisation in Dallas, US. OpenAlex records 7,156 works and 558,184 citations for it. 1,768 researchers list it as their most recent affiliation.
How many works does Texas Health Dallas have?
ScholarIQindexed works
Texas Health Dallas has 7,156 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Texas Health Dallas have?
ScholarIQcitation count
Texas Health Dallas has 558,184 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Texas Health Dallas?
ScholarIQresearcher count
Texas Health Dallas has 1,768 researchers in the ScholarIQ index.
What is the average h-index at Texas Health Dallas?
ScholarIQavg h-index
Texas Health Dallas has an average h-index of 63.3 in OpenAlex.
What is the ROR of Texas Health Dallas?
ScholarIQror
The ROR for Texas Health Dallas is on the source record.
What is the OpenAlex record for Texas Health Dallas?
ScholarIQopenalex
The OpenAlex for Texas Health Dallas is on the source record.
What is the Wikidata of Texas Health Dallas?
ScholarIQwikidata
The Wikidata for Texas Health Dallas is on the source record.
Who are the most-cited researchers behind Texas Health Dallas?
ScholarIQtop researchers by citations
What are the most-cited papers on Texas Health Dallas?
ScholarIQmost cited works
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley Cohen, Karel Pavelká, Ronald van Vollenhoven, John T. Sharp, John L. Perez, G Spencer-Green
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome
Roy Freeman, Wouter Wieling, Felicia B. Axelrod, David G. Benditt, Eduardo E. Benarroch, Italo Biaggioni, William P. Cheshire, Thomas Chelimsky, Pietro Cortelli, Christopher H. Gibbons, David S. Goldstein, R. Hainsworth, Max J. Hilz, Giris Jacob, Horacio Kaufmann, Jens Jordan, Lewis A. Lipsitz, Benjamin D. Levine, Phillip A. Low, Christopher J. Mathias, Satish R. Raj, David Robertson, Paola Sandroni, Irwin J. Schatz, Ron Schondorff, Julian M. Stewart, J. Gert van Dijk
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome
Roy Freeman, Wouter Wieling, Felicia B. Axelrod, David G. Benditt, Eduardo E. Benarroch, Italo Biaggioni, William P. Cheshire, Thomas Chelimsky, Pietro Cortelli, Christopher H. Gibbons, David S. Goldstein, R. Hainsworth, Max J. Hilz, Giris Jacob, Horacio Kaufmann, Jens Jordan, Lewis A. Lipsitz, Benjamin D. Levine, Phillip A. Low, Christopher J. Mathias, Satish R. Raj, David Robertson, Paola Sandroni, Irwin J. Schatz, Ron Schondorf, Julian M. Stewart, J. Gert van Dijk
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson
How much of the research on Texas Health Dallas is open access?
ScholarIQopen access share
33%OPEN ACCESS